SOCS3 and COVID-19: Consistent with previous publications 15-17, SARS-CoV-2 infection was also found to activate interleukin-6 (IL-6)-mediated signaling, which contributes to cytokine release syndrome in severe COVID-19, with representative genes of this pathway including SOCS3 and IL6 (Figure 1B and Table S2).